Maguire LH, Thomas AR, Goldstein AM. Tumors of the neural crest: common themes in development and cancer. Dev Dyn. 2015;244(3):311–22.

PubMed  Article  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

PubMed  Article  Google Scholar 

Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of melanoma. Med Sci (Basel). 2021;9(4):63.

CAS  Google Scholar 

Joyce D, Skitzki JJ. Surgical management of primary cutaneous melanoma. Surg Clin North Am. 2020;100(1):61–70.

PubMed  Article  Google Scholar 

Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011;47(10):1476–83.

CAS  PubMed  Article  Google Scholar 

Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Investig Dermatol. 2006;126(1):154–60.

CAS  PubMed  Article  Google Scholar 

Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Investig Dermatol. 2021;141(1):23–31.

CAS  PubMed  Article  Google Scholar 

Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002–14.

CAS  PubMed  Article  Google Scholar 

Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011;20(1):1–17.

PubMed  PubMed Central  Article  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46.

CAS  PubMed  Article  Google Scholar 

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–36.

CAS  PubMed  Article  Google Scholar 

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9.

PubMed  Article  CAS  Google Scholar 

Atkins MB, Lee SJ, Chmielowski B, Ribas A, Tarhini AA, Truong T-G, et al. DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): a phase III trial—ECOG-ACRIN EA6134. J Clin Oncol. 2021;39(36_suppl):356154.

Article  Google Scholar 

Motaparthi K, Kapil JP, Velazquez EF. Cutaneous squamous cell carcinoma: review of the eighth edition of the American Joint Committee on Cancer Staging Guidelines, Prognostic Factors, and Histopathologic Variants. Adv Anat Pathol. 2017;24(4):171–94.

PubMed  Article  Google Scholar 

Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, Bataille V, Bastholt L, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer. 2020;128:83–102.

CAS  PubMed  Article  Google Scholar 

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–51.

CAS  PubMed  Article  Google Scholar 

Markham A, Duggan S. Cemiplimab: first global approval. Drugs. 2018;78(17):1841–6.

CAS  PubMed  Article  Google Scholar 

Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096–100.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gauci ML, Aristei C, Becker JC, Blom A, Bataille V, Dreno B, et al. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022. Eur J Cancer. 2022;171:203–31.

CAS  PubMed  Article  Google Scholar 

Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell Carcinoma. N Engl J Med. 2016;374(26):2542–52.

CAS  PubMed  PubMed Central  Article  Google Scholar 

D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020;8(1):e000674.

PubMed  PubMed Central  Article  Google Scholar 

Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8(1):48–56.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Haugh AM, Salama AKS, Johnson DB. Advanced melanoma: resistance mechanisms to current therapies. Hematol Oncol Clin North Am. 2021;35(1):111–28.

PubMed  Article  Google Scholar 

Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8.

PubMed  PubMed Central  Article  Google Scholar 

Barila G, Rizzi R, Zambello R, Musto P. Drug conjugated and bispecific antibodies for multiple myeloma: improving immunotherapies off the shelf. Pharmaceuticals (Basel). 2021;14(1):40.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.

PubMed  Article  Google Scholar 

Ortho Multicenter Transplant Study G. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med. 1985;313(6):337–42.

Article  Google Scholar 

Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7(1):9–14.

CAS  PubMed  Article  Google Scholar 

Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–87.

CAS  PubMed  Article  Google Scholar 

Shefet-Carasso L, Benhar I. Antibody-targeted drugs and drug resistance--challenges and solutions. Drug Resist Updat. 2015;18:36–46.

PubMed  Article  Google Scholar 

Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361–70.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Rasmussen SK, Rasmussen LK, Weilguny D, Tolstrup AB. Manufacture of recombinant polyclonal antibodies. Biotechnol Lett. 2007;29(6):845–52.

CAS  PubMed  Article  Google Scholar 

Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793–804.

CAS  PubMed  Article  Google Scholar 

Hoffmann RM, Coumbe BGT, Josephs DH, Mele S, Ilieva KM, Cheung A, et al. Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs). Oncoimmunology. 2018;7(3):e1395127.

PubMed  Article  Google Scholar 

Esnault C, Schrama D, Houben R, Guyetant S, Desgranges A, Martin C, et al. Antibody-drug conjugates as an emerging therapy in oncodermatology. Cancers (Basel). 2022;14(3):778.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Yu B, Liu D. Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2020;13(1):65.

PubMed  PubMed Central  Article  Google Scholar 

Damelin M, Zhong W, Myers J, Sapra P. Evolving strategies for target selection for antibody-drug conjugates. Pharm Res. 2015;32(11):3494–507.

CAS  PubMed  Article  Google Scholar